MAPK inhibitors protect against early‑stage osteoarthritis by activating autophagy
Open Access
- 28 September 2021
- journal article
- research article
- Published by Spandidos Publications in Molecular Medicine Reports
- Vol. 24 (6) , 1-9
Abstract
Osteoarthritis (OA) is a chronic, age‑related osteoarthropathy that causes a considerable decline in quality of life, as well as economic losses due to its high incidence and poor prognosis. Mitogen‑activated protein kinases (MAPKs) regulate multiple cellular processes, including proliferation, differentiation and apoptosis, in certain diseases, such as cancer, diabetes and Alzheimer's disease. The present study aimed to investigate the regulatory role of the MAPK signaling pathway in early‑stage OA. A rabbit model of early‑stage OA was induced by treatment with the enzyme papain. U0126 [an extracellular signal‑regulated kinase (ERK) inhibitor], SP600125 [a Jun NH2‑terminal kinase (JNK) inhibitor] and SB203580 (a p38 inhibitor) were administered to the rabbits via intra‑articular injection. The severity of OA was assessed by histological examination using H&E, toluidine blue and safranin‑O/fast green staining, as well by analyzing the glycosaminoglycan (GAG) content and determining the OA Research Society International (OARSI) score. Western blotting was used to detect the protein expression levels of matrix metalloproteinase‑3 (MMP3), ERK, phosphorylated (p)‑ERK, p38, p‑p38, JNK, p‑JNK, Beclin1, UNC‑51‑like kinase 1 (ULK1) and microtubule‑associated protein 1 light chain 3 (LC3)II/I. U0126, SP600125 or SB203580 treatment significantly decreased the OARSI scores and significantly increased the GAG levels in the cartilaginous tissues of OA model rabbits. These results indicated that the MAPK inhibitors reduced the severity of OA‑induced injury at the early stage. Western blotting results demonstrated that MAPK inhibition significantly decreased the protein expression levels of MMP3 in OA cartilage. The protective effect of MAPK inhibitors in OA was mediated via the activation of autophagy, as demonstrated by the increased protein expression levels of LC3II/I, ULK1 and Beclin1. Overall, the data indicated that MAPK inhibitors may exert a protective effect against OA by restoring compromised autophagy. Furthermore, the present study suggested that MAPK inhibitors may represent a potential pharmacological strategy for treating OA in the future.Keywords
This publication has 41 references indexed in Scilit:
- Autophagy in infection, inflammation and immunityNature Reviews Immunology, 2013
- p38 Mitogen-activated Protein Kinase (MAPK) Promotes Cholesterol Ester Accumulation in Macrophages through Inhibition of MacroautophagyJournal of Biological Chemistry, 2012
- Autophagy: Renovation of Cells and TissuesCell, 2011
- The MAPK cascades: Signaling components, nuclear roles and mechanisms of nuclear translocationBiochimica et Biophysica Acta (BBA) - Molecular Cell Research, 2011
- Regulation of Autophagy by KinasesCancers, 2011
- Autophagy is a protective mechanism in normal cartilage, and its aging‐related loss is linked with cell death and osteoarthritisArthritis & Rheumatism, 2010
- Coordinated regulation of autophagy by p38α MAPK through mAtg9 and p38IPThe EMBO Journal, 2009
- Which elements are involved in reversible and irreversible cartilage degradation in osteoarthritis?Rheumatology International, 2009
- The reliability of the mankin score for osteoarthritisJournal of Orthopaedic Research, 1992
- Effect of Neurotropin on experimental osteoarthritis.Folia Pharmacologica Japonica, 1990